Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142774 · ClinicalTrials.gov registry record · Phase 3
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
A Phase 3 study, sponsored by Organon and.
- Completed
- Registry status
- Phase 3
- Development phase
- 728
- Enrollment target
NCT05142774: Completed Phase 3 study, sponsored by Organon and.
NCT05142774 is a Phase 3 study that has completed, run by Organon and. The registered enrollment target is 728 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05142774, a Phase 3 study, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 728 participants
- Enrollment target
Study Summary
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
Primary Outcome
For rollover subjects, all AEs reported in this extension study were considered as TEAEs except for those AEs ongoing at the end of previous studies but resolved prior to the Visit 1 date for this extension study. For direct-enrolling subjects, all AEs that start after the first dose of study drug will be considered a TEAE.
Interventions
- DRUG Tapinarof cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 3 |
What the finished NCT05142774 record still lists
NCT05142774 is an interventional study that assigns participants to a tested intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Tapinarof cream, 1% is the first listed.
NCT05142774 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05142774 about?
NCT05142774 is a clinical study titled "Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis". This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in ...
What is the current status of trial NCT05142774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 728 participants. The study started on 2021-10-28. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT05142774?
The interventions under investigation include: Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05142774?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05142774's enrollment target sits among peer trials
728 490th of 2000 higher than 1,511 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI